XML 55 R24.htm IDEA: XBRL DOCUMENT v2.4.1.9
OPERATING SEGMENT AND GEOGRAPHIC INFORMATION
 12 Months Ended
Dec. 31, 2014
Segment Reporting [Abstract]  
Operating Segment and Geographic Information
OPERATING SEGMENT AND GEOGRAPHIC INFORMATION
Transgenomic’s chief operating decision-maker is the Chief Executive Officer, who regularly evaluates our performance based on net sales and gross profit. The preparation of this segment analysis requires management to make estimates and assumptions around expenses below the gross profit level. While we believe the segment information to be materially correct, actual results could differ from the estimates and assumptions used in preparing this information.
We have two reportable operating segments, Laboratory Services and Genetic Assays and Platforms. These lines of business are complementary with the Biomarker Identification labs driving innovation and leading to kit production in our Genetic Assays and Platforms segment and new tests in our Patient Testing labs.
The accounting policies of the segments are the same as the policies discussed in Footnote 2 – “Summary of Significant Accounting Policies”.
 
Segment information for the years ended December 31, 2014, 2013 and 2012 is as follows:

 
Dollars in Thousands
 
2014
 
Laboratory Services
 
Genetic Assays and Platforms
 
Total
Net Sales
$
16,520

 
$
10,563

 
$
27,083

Gross Profit
6,840
 
2,881

 
9,721

Net Loss before Taxes
(14,691
)
 
1,273

 
(13,418
)
Income Tax Expense
631

 
(107
)
 
524

Net Loss
$
(15,322
)
 
$
1,380

 
$
(13,942
)
Depreciation/Amortization
$
2,088

 
$
160

 
$
2,248

Interest Expense
406

 
259

 
665

 
December 31, 2014
Total Assets
$
23,116

 
$
6,890

 
$
30,006

Goodwill
6,918

 
—

 
6,918



 
Dollars in Thousands
 
2013
 
Laboratory Services
 
Genetic Assays and Platforms
 
Total
Net Sales
$
15,391

 
$
12,153

 
$
27,544

Gross Profit
6,820

 
3,934

 
10,754

Net (Loss) before Taxes
(12,486
)
 
(3,555
)
 
(16,041
)
Income Tax Expense
—

 
(54
)
 
(54
)
Net (Loss)
$
(12,486
)
 
$
(3,501
)
 
$
(15,987
)
Depreciation/Amortization
$
2,467

 
$
281

 
$
2,748

Interest Expense
398

 
244

 
642

 
December 31, 2013
Total Assets
$
21,711

 
$
8,567

 
$
30,278

Goodwill
6,918

 
—

 
6,918




 
Dollars in Thousands
 
2012
 
Laboratory Services
 
Genetic Assays and Platforms
 
Total
Net Sales
$
19,329

 
$
12,151

 
$
31,480

Gross Profit
9,316

 
3,816

 
13,132

Net Loss before Taxes
(6,874
)
 
(1,307
)
 
(8,181
)
Income Tax Expense
—

 
146

 
146

Net Loss
$
(6,874
)
 
$
(1,453
)
 
$
(8,327
)
Depreciation/Amortization
$
1,960

 
$
318

 
$
2,278

Interest Expense
851

 
37

 
888

 
December 31, 2012
Total Assets
$
29,196

 
$
9,595

 
$
38,791

Goodwill
6,918

 
—

 
6,918


 
Net sales for the year ended December 31, 2014, 2013 and 2012 by country were as follows:
 
 
 
 
Dollars in Thousands
 
 
 
Years Ended December 31,
 
 
 
2014
 
2013
 
2012
United States
 
 
$
21,052

 
$
20,119

 
$
22,727

Italy
 
 
1,258

 
1,530

 
2,524

United Kingdom
 
 
881

 
748

 
1,703

All Other Countries
 
 
3,892

 
5,147

 
4,526

Total
 
 
$
27,083

 
$
27,544

 
$
31,480


Other than the countries specifically identified above, no country individually accounted for more than 5% of total net sales.

More than 99% of our long-lived assets are located within the United States. Substantially all of the remaining long-lived assets are located within Europe.